Petmed Express Inc (PETS) Receives Average Rating of “Hold” from Analysts
Shares of Petmed Express Inc (NASDAQ:PETS) have earned an average recommendation of “Hold” from the eight brokerages that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $42.80.
Several brokerages recently issued reports on PETS. ValuEngine raised shares of Petmed Express from a “hold” rating to a “buy” rating in a report on Wednesday, February 7th. Northcoast Research set a $58.00 target price on shares of Petmed Express and gave the stock a “buy” rating in a report on Wednesday, January 3rd. BidaskClub raised shares of Petmed Express from a “buy” rating to a “strong-buy” rating in a report on Saturday, December 9th. Noble Financial restated a “hold” rating on shares of Petmed Express in a research report on Friday, October 27th. Finally, Zacks Investment Research upgraded shares of Petmed Express from a “sell” rating to a “hold” rating and set a $50.00 price target on the stock in a research report on Friday, October 20th.
In related news, Director Ronald J. Korn sold 5,000 shares of the firm’s stock in a transaction on Monday, January 29th. The shares were sold at an average price of $48.38, for a total transaction of $241,900.00. Following the sale, the director now owns 68,833 shares in the company, valued at $3,330,140.54. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Gian Fulgoni sold 20,000 shares of the firm’s stock in a transaction on Friday, December 15th. The shares were sold at an average price of $44.38, for a total transaction of $887,600.00. Following the sale, the director now owns 55,900 shares in the company, valued at approximately $2,480,842. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 65,000 shares of company stock worth $3,229,500. 4.00% of the stock is owned by company insiders.
Petmed Express (NASDAQ:PETS) opened at $44.06 on Thursday. Petmed Express has a fifty-two week low of $19.21 and a fifty-two week high of $57.80. The stock has a market cap of $903.57, a price-to-earnings ratio of 26.07, a P/E/G ratio of 2.58 and a beta of 0.95.
Petmed Express (NASDAQ:PETS) last issued its earnings results on Monday, January 22nd. The company reported $0.44 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.33 by $0.11. Petmed Express had a net margin of 12.84% and a return on equity of 34.04%. The firm had revenue of $60.10 million during the quarter, compared to analysts’ expectations of $56.76 million. During the same quarter last year, the company posted $0.24 earnings per share. The firm’s revenue was up 13.6% compared to the same quarter last year. analysts anticipate that Petmed Express will post 1.7 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Friday, February 16th. Investors of record on Monday, February 5th will be given a dividend of $0.25 per share. This represents a $1.00 annualized dividend and a yield of 2.27%. The ex-dividend date is Friday, February 2nd. This is a positive change from Petmed Express’s previous quarterly dividend of $0.20. Petmed Express’s dividend payout ratio (DPR) is currently 59.17%.
About Petmed Express
PetMed Express, Inc (PetMed Express), doing business as 1800PetMeds, is a pet pharmacy. The Company markets prescription and non-prescription pet medications, and other health products for dogs and cats, direct to the consumer. It offers a selection of products for dogs and cats. Its product line contains approximately 3,000 stock keeping units (SKUS) of pet medications, health products and supplies.
Receive News & Ratings for Petmed Express Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Petmed Express and related companies with MarketBeat.com's FREE daily email newsletter.